Pennsylvania is currently home to 3309 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects with GlioBlastoma Brain Tumors
NCT05383872
Recruiting
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for liquid biopsy in subjects with suspected Glioblastoma brain tumors
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
12/10/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Glioblastoma, Glioma, Liquid Biopsy
Register for Updates
NASH AMPK Exercise Dosing (AMPED) Trial
NCT04987879
Recruiting
There is no known cure or regulatory agency approved drug therapy for nonalcoholic fatty liver disease (NAFLD), the leading cause of liver disease worldwide, and its progressive type, NASH. This places increased importance on using exercise to treat NAFLD. While physical activity is recommended for all with NAFLD, how to best prescribe exercise as a specific treatment remains unknown, including what dose of exercise is most effective.
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
12/10/2024
Locations: Penn State Hershey Medical Center, Hershey, Pennsylvania
Conditions: NAFLD
Register for Updates
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
NCT04743791
Recruiting
Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: The University of Pittsburgh Asthma Institute at UPMC, Pittsburgh, Pennsylvania
Conditions: Asthma
Register for Updates
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab
NCT04130516
Recruiting
This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and in combination with pembrolizumab. The study will include a dose escalation phase, a dose expansion phase, and phase 2A cohorts. Up to 200 patients will be accrued for this study. Up to 15 study sites in the United States will participate in the study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Solid Tumor, Adult
Register for Updates
A-LiNK: Improving Outcomes in Autoimmune Liver Disease
NCT05750498
Recruiting
The Autoimmune Liver disease Network for Kids (A-LiNK) is a multi-institutional group with the mission to deliver the best care to kids with pediatric autoimmune liver disease (AILD). This study will establish a shared clinical registry and a learning health network for the participating sites focusing on collecting and transmitting clinical measurement data, information about processes, and participation in an improvement collaborative. Pediatric Autoimmune Hepatitis (AIH) and Primary Scleros... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/09/2024
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Register for Updates
eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Cancer
NCT05427240
Recruiting
This randomized non-inferiority study will use a 2x2 design where traditional standard-of-care pre-test (visit 1) and post-test (visit 2: disclosure) counseling delivered by a genetic counselor are replaced with a self-directed web-based eHealth intervention to provide critical data to inform optimal ways to deliver clinical genetic testing in eligible individuals, while maintaining quality of care and favorable cognitive, affective and behavioral outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Cancer
Register for Updates
Study of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia
NCT05320198
Recruiting
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Sargon Research - Pennsylvania Cancer Specialists and Research Center, Gettysburg, Pennsylvania
Conditions: Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes
Register for Updates
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
NCT04098445
Recruiting
Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy and pulmonary morbidity affects as many as 25% of children receiving transplant. Early pulmonary injury includes diffuse alveolar hemorrhage (DAH), thrombotic microangiopathy (TMA) interstitial pneumonitis (IPS) and infection, while later, bronchiolitis obliterans is a complication of chronic GVHD associated with severe morbidity and mortality. Improved diagnosis and treatment of pulmonary complications are urgently need... Read More
Gender:
ALL
Ages:
24 years and below
Trial Updated:
12/09/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Hematopoietic Stem Cell Transplant (HSCT), Diffuse Alveolar Hemorrhage, Thrombotic Microangiopathies, Interstitial Pneumonitis, Bronchiolitis Obliterans
Register for Updates
Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
NCT04047628
Recruiting
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio. All participants will be followed for 72 months after randomization (Day 0, Visit 0).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/09/2024
Locations: Penn Comprehensive MS Center, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Register for Updates
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933
Recruiting
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
12/09/2024
Locations: Children's Hospital of Philadelphia- Center for Childhood Cancer Research, Philadelphia, Pennsylvania
Conditions: Colorectal Adenocarcinoma, Ewing Sarcoma
Register for Updates
Observational Study of HIV+ Deceased Donor Transplant for HIV+ Recipients
NCT02602262
Recruiting
HIV-infected (HIV+) individuals who agree to accept and receive a solid organ transplant from an HIV+ deceased donor will be followed to determine the safety and efficacy of this practice. Some HIV+ individuals who receive a solid organ transplant from HIV-uninfected (HIV-) donors will also be followed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: HIV Infection
Register for Updates
Intrapartum Glucose Control and Risk of Neonatal Hypoglycemia
NCT06643351
Recruiting
The purpose of this study is to assess whether a liberal intrapartum glycemic target range compared to usual care standard control ranges will lead to a decrease in the rate of neonatal hypoglycemia among pregnant patients in labor with diabetes.
Gender:
FEMALE
Ages:
All
Trial Updated:
12/07/2024
Locations: Magee-Women's Hospital of UPMC, Pittsburgh, Pennsylvania
Conditions: Gestational Diabetes Mellitus in Pregnancy, Pregestational Diabetes Mellitus, Neonatal Hypoglycemia
Register for Updates